13 results · 22ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Sterile Posterior Spinal Fixation System

FDA 510(k)
FDA Class 2 ·Orthopedic

CD HORIZON® Spinal System

FDA UDI
MEDTRONIC SOFAMOR DANEK, INC.·00885074362434·SCREW 7221745 HA COATED CANN 7.5 X 45

G-Jet® Transgastric-Jejunal Feeding Device

FDA UDI
APPLIED MEDICAL TECHNOLOGY, INC.·00842071102791·22FR x 1.7 cm x 45 cm Low Profile Transgastric-...

G-Jet® Transgastric-Jejunal Feeding Device

FDA UDI
APPLIED MEDICAL TECHNOLOGY, INC.·00842071117535·22FR x 1.7 cm x 45 cm Low Profile Transgastric-...

VASCLIP

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

MANTARAY GUIDEWIRES

FDA 510(k)
FDA Class 2 ·Cardiovascular

DEXCOM G7 CONTINUOUS GLUCOSE MONITORING SYSTEM

FDA Adverse Event
Malfunction ·DEXCOM, INC.·Product code QBJ·August 13, 2025

CD HORIZON SPINAL SYSTEM

FDA Adverse Event
Injury ·MEDTRONIC SOFAMOR DANEK·Product code KWP·October 1, 2015

MECTALIF ANT - LAG

FDA Adverse Event
Malfunction ·MEDACTA INTERNATIONAL SA·Product code OVD·April 12, 2024

NX3

FDA Adverse Event
Injury ·KERR CORPORATION·Product code EMA·November 7, 2008

FINELINE II STEROX

FDA Adverse Event
Malfunction ·BOSTON SCIENTIFIC·Product code DTB·August 16, 2011

2.5X53MM DISC XS ULNA W/BC LT

FDA Adverse Event
Injury ·BIOMET ORTHOPEDICS·Product code JDC·July 11, 2013

Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration

FDA Enforcement
Class II ·Terminated·St Jude Medical Inc.·October 25, 2017